Forest laboratories inc news - Livemint
Livemint

|E-Paper

×
Home Elections 2018 Companies Industry Politics Money Opinion LoungeMultimedia Science Education Sports TechnologyConsumerSpecials
×
Home » Forest Laboratories Inc

Search Results for Forest Laboratories Inc »

News Videos Slideshows
Pfizer and Allergan were reviewing the treasury department’s announcement Monday night. Photo: AFP

Tue, Apr 05 2016. 10 19 PM IST

Pfizer-Allergan deal faces risk from US inversion rules

The treasury department said the rules would limit companies’ ability to participate in inversion transactions if they’ve already done them within the past 36 months

Executives at Pfizer prefer to strike a deal with AstraZeneca, and the US company isn’t likely to make a move on an alternative target anytime soon. Photo: AFPm

Thu, Aug 21 2014. 09 52 AM IST

AstraZeneca is tougher Pfizer target as possible new bid looms

Pfizer isn’t giving up on gaining a new pipeline of drugs, even as the potential cost of acquiring AstraZeneca rises

Glenmark expects to obtain approval for the initiation of clinical studies for the drug during this fiscal year.

Wed, Aug 20 2014. 12 04 PM IST

Glenmark develops new anti-cancer drug

The firm expects to obtain approval for initiation of clinical studies for the drug during this fiscal year

Phase II trials typically evaluate the effectiveness of an experimental therapy in treating a medical condition. Photo: Bloomberg

Thu, May 15 2014. 12 08 AM IST

Sanofi junks Glenmark’s painkiller molecule

This is the second major blow for Glenmark this year after it lost a patent suit to Abbott Laboratories in the US in March

Forest Laboratories said that it agreed to sell Furiex royalties on two products to Royalty Pharma for about $415 million upon completion of the acquisition. Photo: Bloomberg

Mon, Apr 28 2014. 09 14 PM IST

Forest Laboratories to acquire Furiex for $1.1 billion

Forest will pay about $95 a share for Furiex, and up to $30 a share in a contingent value right for Furiex’s eluxadoline

The biggest drugmakers are reshuffling units to get rid of ones that don’t make them leaders in a particular market, while smaller players are buying competitors to add size, lest they be swallowed up themselves. Photo: AFP

Wed, Apr 23 2014. 12 42 PM IST

Global pharma looks at be-first or get out strategy

Generic-drug makers are buying up more profitable injectable and brand-name drugs in a bid to grow bigger than rivals

Photo: Bloomberg

Fri, Apr 11 2014. 12 33 PM IST

Carl Icahn backs down from demand that eBay spin off PayPal

The billionaire investor failed to drum up support from the e-commerce company’s major shareholders

The SFR logo sits on display inside a mobile phone store operated by Vivendi SA in Paris. Photo: Balint Porneczi/Bloomberg

Sat, Apr 05 2014. 10 16 PM IST

Vivendi agrees to sell SFR to Altice in $23 billion deal

Vivendi to get €13.5 bn in cash now and €750 mn later and 20% of a company created from the merger

Glenmark shares were trading at Rs582.25 apiece on the BSE in afternoon trade, up 0.15% from its previous close.

Tue, Mar 25 2014. 07 07 PM IST

Glenmark receives $4 million from Forest Lab as research fee

Glenmark has received $4 million as research fee for the development of novel mPGES-1 inhibitors to treat chronic inflammatory conditions

Sun has expanded in the last few years, mainly through acquisitions, and Uday Baldota—senior vice president for finance and accounts —said the company was on the look out for more purchases. Photo: Hemant Mishra/Mint

Thu, Mar 06 2014. 02 43 PM IST

Sun Pharma seeks to enter Japan generics market

Mumbai-based Sun gets more than half its sales from the US, the world’s biggest pharmaceuticals market

123Next »